Tenofovir Prodrug Achieves 99% Viral Load Reduction in Hepatitis B Patients Head-to-head trial compares treatment with Viread


The trial is designed to enroll 60 treatment-naïve patients. The sequential dose- escalation format consists of 10 patients per cohort receiving four weeks of a once-daily dose of 5, 10, 25, 50, and 100 mg of CMX157, respectively, plus two patients per cohort receiving 300 mg of TDF, the standard therapeutic dose of Viread.

The patients have successfully completed the 5-mg and 10-mg cohorts. The new interim data were derived from 10 HBV-infected patients who completed 14 days of once-daily oral dosing of 25 mg of CMX157, and two HBV patients treated for 14 days of oral dosing with 300 mg TDF. The CMX157-treated patients showed an average 99% reduction in the HBV viral load compared with baseline. Significantly, the observed antiviral activity for CMX157 was comparable with that observed in TDF-treated patients, but at one-twelfth the dose (25 mg of CMX157 versus the standard 300 mg of TDF).



Delaware Valley University, Hepatitis B Foundation reach agreement on biotechnology center dispute

Delaware Valley University will receive $2 million in exchange for giving up its stake in the Pennsylvania Biotechnology Center in Buckingham, the scientific research center and business incubator it founded more than 10 years ago in partnership with the nonprofit Hepatitis B Foundation.

The agreement, announced by the university and foundation in a joint statement Thursday, brings to an end a contentious battle over control of the center. It also paves the way for a long-awaited, $10.6 million expansion of the center to accommodate the needs of existing and future tenants.

“While both partners have been committed to the success of the center, different visions have arisen over the governance, management and future of the center,” the university and foundation said. “After significant negotiations, the partners have mutually agreed to terminate the partnership. They have satisfied themselves that while their expectations and visions for the center may differ, they are each motivated by the continued success of the center.”

Read more….


Those vaccinated against hepatitis B as neonates frequently require re-vaccination as young adults | WCHLD


  • Data support the need to perform a pre-booster check for anti-HB antibody titer prior to HB re-vaccination among a population of young adult patients who received neonatal HB vaccination.

Key results

  • Of 408 subjects, 3 (0.7%) were HBsAg-positive and 332 (81.4%) were anti-HBs negative or titer <10 mlU/mL. A total of 76 (18.6%) had anti-HB titer ≥10 mlU/ml.
  • Those who had anti-HB titer <10 mlU/ml required at least 2 doses of HB vaccine to achieve protective levels of anti-HBV.


Read more….


New Biomarker May Identify Patients at Risk for Hep B Recurrence During Immunosuppressive Therapy | Özge Özkaya

People with hepatitis B core-related antigen (HBcrAg) in their blood are nearly three times more likely to experience hepatitis B virus (HBV) recurrence when undergoing immunosuppressive therapy than those who do not, according to a study published in theAmerican Journal of Gastroenterology.

This finding suggests that HBcrAg can be used as a new biomarker to identify patients at high risk, and who may benefit from antiviral therapy. The study is titled Association of Hepatitis B Core-Related Antigen With Hepatitis B Virus Reactivation in Occult Viral Carriers Undergoing High-Risk Immunosuppressive Therapy.

A research team from the Department of Medicine at Queen Mary Hospital at The University of Hong Kong monitored the level of HBcrAg in the blood of 124 Asian patients every four weeks for up to two years.

Read more….